
Personalisation of therapy for people with type 2 diabetes and cardiovascular disease risk
Feb 14, 2024 - 00:11:56
Radio and PodcastLive Radio & Podcasts
Heterogeneity across available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes means that agents should be prescribed based on patient characteristics and preferences. So how can we best make th...